lilly glp 1 small molecule Beyond the Needle: Eli Lilly's Orforglipron and the GLP-1 Revolution What's Coming Next for GLP-1
Description
Evolv | 1,544 followers on LinkedIn
Easy to incorporate into your daily wellness routine
Real Results You Can Expect
Glucagon-like peptide 1 (GLP1) analogues are licensed options for obesity, but new treatments are required to obtain better weight loss and to directly address other co-morbidities, such as non-alcoholic fatty liver disease
Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)
